Radelumin is a modern radiopharmaceutical that has gained recognition in recent years for the diagnosis of prostate cancer. Registered and approved for use in the territory of the Republic of Poland, Radelumin contains a ligand with high specificity for the prostate-specific membrane antigen (PSMA). This ligand is labeled with the isotope ¹⁸F, which emits positrons, enabling its application in positron emission tomography (PET) technology. Thanks to this innovative technology, Radelumin serves as a significant tool in the precise diagnosis of prostate cancer.
The radiopharmaceutical operates based on selective binding to PSMA, a protein expressed on the surface of prostate cancer cells. The ligand contained in the preparation binds to PSMA, facilitating its internalization via receptor-mediated endocytosis. As a result of this process, the radioactive isotope ¹⁸F accumulates inside cancer cells, producing a clear image during PET/MR and PET/CT examinations.
PET technology, owing to its high resolution and imaging accuracy, allows for the detection of both primary tumor sites and metastases. The precise images obtained during PET scans using Radelumin enable the assessment of disease stage, which is invaluable for therapeutic decision-making.
Indications for Application
Radelumin is used in the diagnosis of prostate cancer, particularly in the following cases:
- Initial assessment of disease staging – in patients with high-risk prostate cancer prior to the commencement of radical treatment. The use of Radelumin enables physicians to more accurately evaluate tumor spread and determine the most appropriate treatment strategy.
- Diagnosis of biochemical recurrence – in patients who experience a rise in prostate-specific antigen (PSA) levels following prior radical treatment (e.g., prostatectomy or radiotherapy). An increase in PSA may indicate cancer recurrence, and Radelumin allows for precise localization of tumor sites potentially responsible for this rise.
Benefits of Radelumin application
High specificity and sensitivity – thanks to its unique binding mechanism to PSMA, Radelumin provides high specificity and sensitivity in detecting cancerous lesions, enabling identification of prostate cancer foci at a very early stage.
Imaging precision – the PET/MR technique allows acquisition of high-resolution images that enable accurate assessment of the location and spread of both primary and metastatic cancerous lesions.
Safe elimination from the body – Radelumin is metabolized in the liver and subsequently excreted mainly via the hepatobiliary (bile) route. As a result, patients do not need to worry about long-term side effects related to accumulation of the agent in the body.
After intravenous administration, the radiopharmaceutical undergoes hepatic metabolism and is then excreted into the bile ducts and intestines. Unlike agents labeled with the isotope ⁶⁸Ga, which are primarily eliminated via the urinary tract, Radelumin utilizes the biliary pathway.
From a diagnostic perspective, this means that Radelumin does not accumulate in the urinary bladder, allowing for more precise imaging within the pelvic region, particularly in the context of detecting very early local recurrence in the postoperative bed. Indications for the use of Radelumin and gallium-based agents are similar, but differences in the elimination pathways may have clinical significance in certain diagnostic situations.
Thanks to these differences, Radelumin represents a valuable alternative to other agents used in PET diagnostics, offering more precise imaging and better control over the elimination process.
Clinical applications
Radelumin is becoming an increasingly popular tool in clinical practice, particularly in the diagnosis of early-stage prostate cancer, as well as in monitoring patients after radical treatment who may require ongoing surveillance. Modern imaging technologies enable early detection of cancer recurrence, which improves the chances of effective treatment and enhances patient prognosis.
